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However, an issue yet to be addressed is the true definition of 'clinically significant' prostate cancer. Here, the authors use a pathological definition that has not been clinically verified: cancer volume of less than 0.5 ml, Gleason score of 6 or less, and organ-confined disease. this definition is based on conjecture rather than mature clinical data. a more relevant clinical defini tion of significant cancer depends on careful considera tion of the patient's life expectancy, as well as the tumor, and an estimation of the likelihood that a cancer will cause clinical symptoms during a patient's lifetime. investigators addressing this issue have concluded that the vast majority of Psa-detected asymptomatic Gleason 6 (3 + 3) cancers, even if untreated, are unlikely to be associated with a cancerrelated death during 15 years of followup. 7 Based on these and other data, it is my assessment that the clinical relevance of asymptomatic tumors with a Gleason sum of 6 or less is substantially over estimated. the real issue is not the Gleason 6 tumor, but the patient whose biopsy contains a Gleason 6 tumor and whose prostate harbors a biopsy-undetected higher grade lesion.
though successful focal therapies promise the trifecta, it is important to remember that many, if not most, prostate cancers detected by Psa screening are unlikely to harm the patient in their lifetime. 8, 9 Perhaps it is better to simply avoid treatment of any sort in patients considered suitable for this approach. Better prospective studies regarding the issue of who does and does not need treatment for clinically localized prostate cancer remains one of the most pressing needs in all of medicine today. the existence of poor overall survival among socioeconomically disadvantaged men with prostate cancer has been well established; 1,2 however, the underlying reasons remain unclear. Certainly, men with lower socio economic status typically present with more-advanced disease. 1, 3 while this fact suggests a difference in screening practice patterns and perhaps in risk factors, stage-adjusted differences in treatment patterns might also exist. such differences are particularly relevant in any country with a socialized health-care system, such as the uK, where equity of screening and treatment patterns is expected.
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to address this issue, lyratzopoulos et al. 3 examined a large cohort of British men with recently diagnosed prostate cancer from a population-based cancer registry and studied the likelihood of active treatment according to socioeconomic status. they found that men from lower socioeconomic groups were significantly less likely than those from higher groups to be treated with radical surgery or radiotherapy, regardless of age, stage, diagnosis period, tumor type, or hospital type. importantly, despite having a greater risk of higher-stage disease at initial diagnosis, men with lower socioeconomic status were actually more likely to receive watchful waiting than men with higher socioeconomic status. these results support other research suggesting that the substantial differences in survival between men from different socioeconomic backgrounds might be partly attributable to varia tion in treatment patterns and not just to variation in screening practice patterns.
2,4,5 of course, sorting through the multitude of factors that influence socioeconomic status is a highly complex enterprise. For one, a range of surrogates for socio economic status has been used in the literature, 1,2,4-6 including income, education, and military rank, which makes defining socioeconomic status difficult and comparing studies impractical. additionally, the effects of race and ethnicity have been difficult to distinguish from those of socioeconomic status owing to their frequent co-occurrence. For example, within the usa, black men are generally poorer and less-educated than white men, with significant disparities seen in prostate cancer treatments received. 4 thus, identifying whether these differences arise from race, socioeconomic status, or a combination thereof is not an easy task. studies that have examined race and socioeconomic factors in prostate cancer survival, however, have suggested that differences in treatment patterns based on socioeconomic 
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status are a significant contributor to the survival disadvantage seen in black men. 1, 2 in their study, lyratzopoulos et al. 3 used a national index of socioeconomic status that takes into account income, employment, health, education, and crime, among other variables. as their population was nearly all white, race and ethnicity were nonfactors. of note, the British national Health service is essentially a single-payer, socialized healthcare system, with only a small fraction of the population covered by private health insurance. although no screening data were given, the investigators controlled for possible screening disparities by adjusting for disease stage and found that low socioeconomic status remained an independent predictor of treatment by watchful waiting. while large randomized comparisons of active treatment versus watchful waiting are pending, one trial in scandinavia found a survival benefit for radical prostat ectomy over watchful waiting. 7 additionally, a large retrospective study in the usa compared watchful waiting to active treatment and found a survival advantage in elderly men who pursued active treatment for low-risk and inter mediaterisk prostate cancer. 6 Given that these studies suggest that active treatment results in a survival advantage, the key healthcare questions are why socio economically dis advantaged patients choose watchful waiting, and whether they are biased towards that choice by their physicians.
these questions may never be completely answered, but they underscore the importance of transparency and education in the doctor-patient relationship. one study of the treatment decision-making process found that 51% of men with localized prostate cancer ranked their physician's recommenda tions as the most important factor influencing their treatment decision, followed by advice from family and friends (19%) and information from books and journals (18%). 8 as prostate cancer management should be based on clinical parameters including overall comorbidities and patient preferences rather than socioeconomic background, physicians should be mindful of their own potential biases and influence on patient treatment decision-making. any recommendations of treatment for newly diagnosed prostate cancer should stem solely from evidence-based medicine, and ideally from randomized clinical trials when available.
lyratzopoulos et al. 3 do, however, have several limitations to their study, which must be taken into consideration. serum Psa levels, biopsy Gleason grade, and comorbidities, which were not considered in their study, have proven extremely helpful in stratifying patients according to clinical risk, which can influence treatment decisions. one large study in the usa found tumor grade, ahead of socioeconomic factors such as income, education, and geographic region, to be the strongest predictor of radical surgery or radiation therapy in men diagnosed with localized or locally advanced prostate cancer. 5 additionally, although lyratzopoulos and colleagues 3 do address their lack of data on comorbidities, they suggest that comorbidities would influence the selection of patients for surgery but not for radiotherapy. while it may be true (although unproven) that comorbidities influence the decision for surgery more than for radiotherapy, comorbidities and thus anticipated life expectancy are likely to have a vital role in choosing between radiotherapy versus no therapy, which have drastically different outcomes. 2 in the usa, furthermore, patients with prostate cancer have shown much greater preference for radical surgery over radiotherapy, 9 which increases the importance of comorbidities in determining prostate cancer management. lastly, and perhaps most importantly, lyratzopoulos et al. 3 fail to examine the impact of their findings on overall and cancer-specific survival, which would have drastically enhanced the clinical significance of their findings.
whether physicians involuntarily discriminate against men with lower socio economic status remains unclear and perhaps never will be fully answered. with implications for patient survival, however, treatment prescribed by physicians must adhere to a stringent protocol based on high-quality evidence, which unfortunately is still lacking. we hope that the ongoing Prostate Cancer intervention versus observation trial (Pivot; comparing radical prostat ectomy to watchful waiting) 10 will help to clarify the role of primary therapy in this disease, although stage migration over the more than 10 years since Pivot began might limit the relevance of any findings for patients diagnosed today. ultimately, once more data are available and the optimum treatment strategy for prostate cancer is clear, we hope that the well-documented disparities in quality of care will cease to exist.
